Soft Tissue Sarcoma

News alerts, weekly reports and conference planners

Related cancers:

KIT exon 17 mutation	Gastrointestinal Stromal Tumor	KIT exon 17 mutation	Gastrointestinal Stromal Tumor	ripretinib Sensitive: B - Late Trials ASCO-GI 2023 - 2 weeks (New C3) ripretinib Sensitive : B ASCO-GI 2023 - 2wk	ripretinib Sensitive: B - Late Trials ASCO-GI 2023 - 2 weeks ripretinib Sensitive : B ASCO-GI 2023 - 2 weeks - (New C3)
KIT exon 11 mutation	Gastrointestinal Stromal Tumor	KIT exon 11 mutation	Gastrointestinal Stromal Tumor	ripretinib Sensitive: B - Late Trials ASCO-GI 2023 - 2 weeks (New C3) ripretinib Sensitive : B ASCO-GI 2023 - 2wk	ripretinib Sensitive: B - Late Trials ASCO-GI 2023 - 2 weeks ripretinib Sensitive : B ASCO-GI 2023 - 2 weeks - (New C3)
KIT exon 18 mutation	Gastrointestinal Stromal Tumor	KIT exon 18 mutation	Gastrointestinal Stromal Tumor	ripretinib Sensitive: B - Late Trials ASCO-GI 2023 - 2 weeks (New C3) ripretinib Sensitive : B ASCO-GI 2023 - 2wk	ripretinib Sensitive: B - Late Trials ASCO-GI 2023 - 2 weeks ripretinib Sensitive : B ASCO-GI 2023 - 2 weeks - (New C3)
KIT positive	Gastrointestinal Stromal Tumor	KIT positive	Gastrointestinal Stromal Tumor	imatinib Sensitive: A1 - Approval imatinib Sensitive : A1	imatinib Sensitive: A1 - Approval imatinib Sensitive : A1
PDGFRA D842V	Gastrointestinal Stromal Tumor	PDGFRA D842V	Gastrointestinal Stromal Tumor	avapritinib Sensitive: A1 - Approval avapritinib Sensitive : A1	avapritinib Sensitive: A1 - Approval avapritinib Sensitive : A1
No biomarker	Soft Tissue Sarcoma	No biomarker	Soft Tissue Sarcoma	olaratumab Sensitive: A1 - Approval olaratumab Sensitive : A1	olaratumab Sensitive: A1 - Approval olaratumab Sensitive : A1
No biomarker	Gastrointestinal Stromal Tumor	No biomarker	Gastrointestinal Stromal Tumor	sunitinib Sensitive: A1 - Approval sunitinib Sensitive : A1	sunitinib Sensitive: A1 - Approval sunitinib Sensitive : A1
No biomarker	Soft Tissue Sarcoma	No biomarker	Soft Tissue Sarcoma	trabectedin Sensitive: A1 - Approval trabectedin Sensitive : A1	trabectedin Sensitive: A1 - Approval trabectedin Sensitive : A1
No biomarker	Liposarcoma	No biomarker	Liposarcoma	eribulin mesylate Sensitive: A1 - Approval eribulin mesylate Sensitive : A1	eribulin mesylate Sensitive: A1 - Approval eribulin mesylate Sensitive : A1
No biomarker	Soft Tissue Sarcoma	No biomarker	Soft Tissue Sarcoma	pazopanib Sensitive: A1 - Approval pazopanib Sensitive : A1	pazopanib Sensitive: A1 - Approval pazopanib Sensitive : A1
No biomarker	Leiomyosarcoma	No biomarker	Leiomyosarcoma	trabectedin Sensitive: A1 - Approval trabectedin Sensitive : A1	trabectedin Sensitive: A1 - Approval trabectedin Sensitive : A1
No biomarker	Liposarcoma	No biomarker	Liposarcoma	trabectedin Sensitive: A1 - Approval trabectedin Sensitive : A1	trabectedin Sensitive: A1 - Approval trabectedin Sensitive : A1
No biomarker	Gastrointestinal Stromal Tumor	No biomarker	Gastrointestinal Stromal Tumor	ripretinib Sensitive: A1 - Approval ripretinib Sensitive : A1	ripretinib Sensitive: A1 - Approval ripretinib Sensitive : A1
PDGFRA exon 18 mutation	Gastrointestinal Stromal Tumor	PDGFRA exon 18 mutation	Gastrointestinal Stromal Tumor	avapritinib Sensitive: A1 - Approval avapritinib Sensitive : A1	avapritinib Sensitive: A1 - Approval avapritinib Sensitive : A1
No biomarker	Fibrosarcoma	No biomarker	Fibrosarcoma	imatinib Sensitive: A1 - Approval imatinib Sensitive : A1	imatinib Sensitive: A1 - Approval imatinib Sensitive : A1
No biomarker	Kaposi Sarcoma	No biomarker	Kaposi Sarcoma	pegylated liposomal doxorubicin Sensitive: A1 - Approval pegylated liposomal doxorubicin Sensitive : A1	pegylated liposomal doxorubicin Sensitive: A1 - Approval pegylated liposomal doxorubicin Sensitive : A1
No biomarker	Kaposi Sarcoma	No biomarker	Kaposi Sarcoma	pomalidomide Sensitive: A1 - Approval pomalidomide Sensitive : A1	pomalidomide Sensitive: A1 - Approval pomalidomide Sensitive : A1
No biomarker	Soft Tissue Sarcoma	No biomarker	Soft Tissue Sarcoma	tazemetostat Sensitive: A1 - Approval tazemetostat Sensitive : A1	tazemetostat Sensitive: A1 - Approval tazemetostat Sensitive : A1
No biomarker	Rhabdomyosarcoma	No biomarker	Rhabdomyosarcoma	dactinomycin Sensitive: A1 - Approval dactinomycin Sensitive : A1	dactinomycin Sensitive: A1 - Approval dactinomycin Sensitive : A1
No biomarker	Soft Tissue Sarcoma	No biomarker	Soft Tissue Sarcoma	doxorubicin hydrochloride Sensitive: A1 - Approval doxorubicin hydrochloride Sensitive : A1	doxorubicin hydrochloride Sensitive: A1 - Approval doxorubicin hydrochloride Sensitive : A1
No biomarker	Gastrointestinal Stromal Tumor	No biomarker	Gastrointestinal Stromal Tumor	regorafenib Sensitive: A1 - Approval regorafenib Sensitive : A1	regorafenib Sensitive: A1 - Approval regorafenib Sensitive : A1
KIT expression	Gastrointestinal Stromal Tumor	KIT expression	Gastrointestinal Stromal Tumor	imatinib Sensitive: A1 - Approval imatinib Sensitive : C1	imatinib Sensitive: A1 - Approval imatinib Sensitive : C1
No biomarker	Soft Tissue Sarcoma	No biomarker	Soft Tissue Sarcoma	atezolizumab Sensitive: A1 - Approval atezolizumab Sensitive : A1	atezolizumab Sensitive: A1 - Approval atezolizumab Sensitive : A1
No biomarker	Soft Tissue Sarcoma	No biomarker	Soft Tissue Sarcoma	ifosfamide + epirubicin + mesna Sensitive: A2 - Guideline ifosfamide + epirubicin + mesna Sensitive : A2	ifosfamide + epirubicin + mesna Sensitive: A2 - Guideline ifosfamide + epirubicin + mesna Sensitive : A2
No biomarker	Soft Tissue Sarcoma	No biomarker	Soft Tissue Sarcoma	AIM Sensitive: A2 - Guideline AIM Sensitive : A2	AIM Sensitive: A2 - Guideline AIM Sensitive : A2
No biomarker	Rhabdomyosarcoma	No biomarker	Rhabdomyosarcoma	IE Sensitive: A2 - Guideline IE Sensitive : A2	IE Sensitive: A2 - Guideline IE Sensitive : A2
NTRK3 fusion	Soft Tissue Sarcoma	NTRK3 fusion	Soft Tissue Sarcoma	entrectinib Sensitive: A2 - Guideline entrectinib Sensitive : A2	entrectinib Sensitive: A2 - Guideline entrectinib Sensitive : A2
No biomarker	Soft Tissue Sarcoma	No biomarker	Soft Tissue Sarcoma	GT Sensitive: A2 - Guideline GT Sensitive : A2	GT Sensitive: A2 - Guideline GT Sensitive : A2
NTRK2 fusion	Gastrointestinal Stromal Tumor	NTRK2 fusion	Gastrointestinal Stromal Tumor	entrectinib Sensitive: A2 - Guideline entrectinib Sensitive : A2	entrectinib Sensitive: A2 - Guideline entrectinib Sensitive : A2
NTRK1 fusion	Gastrointestinal Stromal Tumor	NTRK1 fusion	Gastrointestinal Stromal Tumor	entrectinib Sensitive: A2 - Guideline entrectinib Sensitive : A2	entrectinib Sensitive: A2 - Guideline entrectinib Sensitive : A2
NTRK3 fusion	Gastrointestinal Stromal Tumor	NTRK3 fusion	Gastrointestinal Stromal Tumor	entrectinib Sensitive: A2 - Guideline entrectinib Sensitive : A2	entrectinib Sensitive: A2 - Guideline entrectinib Sensitive : A2
No biomarker	Uterine Corpus Leiomyosarcoma	No biomarker	Uterine Corpus Leiomyosarcoma	pazopanib Sensitive: A2 - Guideline pazopanib Sensitive : A2	pazopanib Sensitive: A2 - Guideline pazopanib Sensitive : A2
No biomarker	Rhabdomyosarcoma	No biomarker	Rhabdomyosarcoma	VAC Sensitive: A2 - Guideline VAC Sensitive : A2	VAC Sensitive: A2 - Guideline VAC Sensitive : A2
No biomarker	Soft Tissue Sarcoma	No biomarker	Soft Tissue Sarcoma	ifosfamide Sensitive: A2 - Guideline ifosfamide Sensitive : A2	ifosfamide Sensitive: A2 - Guideline ifosfamide Sensitive : A2
NTRK3 fusion	Gastrointestinal Stromal Tumor	NTRK3 fusion	Gastrointestinal Stromal Tumor	larotrectinib Sensitive: A2 - Guideline larotrectinib Sensitive : A2	larotrectinib Sensitive: A2 - Guideline larotrectinib Sensitive : A2

Soft Tissue Sarcoma

Associations(395)

Associations
(395)